Infinity Pharmaceuticals (NASDAQ:INFI) Receives New Coverage from Analysts at StockNews.com

Investment analysts at StockNews.com began coverage on shares of Infinity Pharmaceuticals (NASDAQ:INFI – Get Free Report) in a research report issued to clients and investors on Monday. The firm set a “hold” rating on the biotechnology company’s stock. Infinity Pharmaceuticals Price Performance NASDAQ:INFI opened at $0.01 on Monday. The stock’s fifty day simple moving average […]

Related Keywords

Adeleneq Perkins , ,Infinity Pharmaceuticals Company Profile ,Infinity Pharmaceuticals Inc ,Millennium Management ,Charles Schwab Investment Management Inc ,Infinity Pharmaceuticals ,Goldman Sachs Group Inc ,Insider Activity At Infinity Pharmaceuticals ,Nasdaq ,Securities Exchange Commission ,News Ratings For Infinity Pharmaceuticals Daily ,Infinity Pharmaceuticals Price Performance ,Get Free Report ,Director Adelene ,Exchange Commission ,Street Corp ,Schwab Investment Management ,Goldman Sachs Group ,Sachs Group ,Infinity Pharmaceuticals Daily ,Nasdaq Infi ,Infi ,Medical ,45665g30 ,Initiated Coverage ,Stocknews Com ,